Heterologous COVID-19 vaccines intervention effect on reactogenicity
To determine the change in the occurrence of short-term vaccine reactions on the use of heterologous Covid-19 booster, a single centre short-term study of two months duration was conducted. It was designed as an interventional study with registered clinical trial number # SLCTR/2022/008. It was conducted on medical students and faculty of a National university of medical sciences, Rawalpindi affiliated public sector medical college. A total of 348 individuals were administered with Ad5-nCoV vaccine and 101 with mRNA-1273 vaccine. They all had been previously vaccinated with two doses of BBIBP-CorV. BBIBP-CorV reactogenicity was considered a control group. Vaccine reactions, including pain and redness at the injection site, fever, no observed reactions at all, myalgia, feeling cold, dizziness, paraesthesia in the arm, lightheadedness, had a significant change in their frequencies in comparison to homologous vaccine (BBIBP-CorV) reactogenicity. It was concluded that mixing and matching of COVID-19 vaccines result in an increase in frequency of post-vaccine short-term reactions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
JPMA. The Journal of the Pakistan Medical Association - 74(2024), 1 vom: 14. Jan., Seite 134-137 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Najeeb, Wajeha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 24.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.47391/JPMA.8615 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367097265 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367097265 | ||
| 003 | DE-627 | ||
| 005 | 20240125232058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.47391/JPMA.8615 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1270.xml |
| 035 | |a (DE-627)NLM367097265 | ||
| 035 | |a (NLM)38219181 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Najeeb, Wajeha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heterologous COVID-19 vaccines intervention effect on reactogenicity |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a To determine the change in the occurrence of short-term vaccine reactions on the use of heterologous Covid-19 booster, a single centre short-term study of two months duration was conducted. It was designed as an interventional study with registered clinical trial number # SLCTR/2022/008. It was conducted on medical students and faculty of a National university of medical sciences, Rawalpindi affiliated public sector medical college. A total of 348 individuals were administered with Ad5-nCoV vaccine and 101 with mRNA-1273 vaccine. They all had been previously vaccinated with two doses of BBIBP-CorV. BBIBP-CorV reactogenicity was considered a control group. Vaccine reactions, including pain and redness at the injection site, fever, no observed reactions at all, myalgia, feeling cold, dizziness, paraesthesia in the arm, lightheadedness, had a significant change in their frequencies in comparison to homologous vaccine (BBIBP-CorV) reactogenicity. It was concluded that mixing and matching of COVID-19 vaccines result in an increase in frequency of post-vaccine short-term reactions | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 vaccines, Booster immunisation,Adverse effects. | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a Ad5-nCoV vaccine |2 NLM | |
| 650 | 7 | |a 5AHC3V2UQS |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Waheed, Palvasha |e verfasserin |4 aut | |
| 700 | 1 | |a Khadim, Rehana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JPMA. The Journal of the Pakistan Medical Association |d 1977 |g 74(2024), 1 vom: 14. Jan., Seite 134-137 |w (DE-627)NLM000033170 |x 0030-9982 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2024 |g number:1 |g day:14 |g month:01 |g pages:134-137 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.47391/JPMA.8615 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2024 |e 1 |b 14 |c 01 |h 134-137 | ||